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Abstract
Radionuclide therapy has been an integral part of systemic 
treatment of patients with advanced and disseminated cancer 
for 50 years. Specific radioisotopes (b- or a-emitters) with se-
lective concentration at sites of bone cancer damage are used 
in the treatment. Radioisotopes are an important addition to 
the armamentarium of clinicians who take care of patients with 
advanced cancer and painful cancer bone metastases (espe-
cially osteoblastic and mixed type). They offer a high degree of 
efficacy with minimal toxicity and simple administration, fulfill-
ing the fundamental criteria for palliative treatment that should 
combine minimal patient discomfort and toxicity with maximal 
clinical effect.
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Introduction
Due to constantly increasing neoplastic disease incidence, 
bone metastases are becoming a more and more serious issue 
in oncology. As regards the most common tumours, half of them 
are connected with a high probability of developing metastases to 
the skeletal system. Bones, next to lungs and liver, are among the 
top three sites of distant metastases localization. Neoplasms that 
give metastases to the skeletal system are most frequently can-
cers of the prostate, breast, kidneys, lungs, and thyroid (Table I). 
These metastases are located mainly in the so-called cancel-
lous bones that have good vascularization connected with a large 
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amount of active haematopoietic marrow. This is enhanced by 
slower blood flow through sinusoid vessels [1]. The scheme of 
bone metastasis formation is presented in Figure 1 [2]. 
Bone matrix remodelling occurs as a consequence of neoplas-
tic cell presence. In healthy bone the balance between process-
es of ossification and resorption is maintained. They always take 
place in one way that is genetically programmed and modified by 
particular external and internal factors. A fundamental role in bone 
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Bone metastasis
Infiltrate of lymphatic or blood vessel walls through primary tumour
Ø
Dissemination of neoplastic cells to the bloodstream
Ø
Neoplastic cell colonization in bone marrow
Ø
Neoplastic cell extravasation:
adherence to endothelium Æ endothelium spasm Æ adherence to 
basement membrane Æ basement membrane dissolution Æ neoplastic 
cell movement to marrow stroma (enhancing factors: large spaces 
between endothelium cells, fragmentary lack of basement membrane 
in sinusoid vessels of bone marrow, chemotactic effect of some 
substances that occur neutrally in bone tissue, e.g. type I collagen, 
growth factors)
Ø
Bone infiltrate with modification of the surroundings
Ø
Damage to old and/or formation of new bone tissue
Figure 1. Scheme of bone metastasis formation.
Table 1. Frequency of advanced stage bone metastases
Primary lesion Frequency of bone metastases occurrence
Prostate 70–80%
Breast 73%
Thyroid 42%
Lungs 36%
Kidneys 35%
Digestive tract 5%
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remodelling processes is played by two types of cell that have 
different functions and origins: osteogenic cells — osteoblasts, 
and resorption cells — osteoclasts.
Osteoblasts have an approximate life time of 3 months and 
come from mesenchymoma multipotential matrix cells. They 
produce type I collagen and proteoglycans that form the organic 
intracellular structure of the bone which is further calcified. Osteob-
lasts are also responsible for synthesis of osteonectin, osteopontin, 
osteocalcin, and various types of proteinase [3, 4]. 
Osteoclasts, the life time of which amounts to approximately 2 
weeks, come from a monocyte-macrofagal line of haematopoietic 
cells that, after differentiation, connect and build active polynucle-
ated forms. Large amounts of carbonic anhydrase in osteoclast 
enable separation of H+ from H2CO3 and then its removal directly 
to the surrounding bone, which initiates the osteolysis process. 
Osteoclasts have the ability to phagocytise bone and then digest 
it within its cytoplasm. An important factor for osteoclast function 
is negative feedback in which apoptosis inducing factors are 
organic bone matrix degradation products. The products of bone 
matrix degradation as well as local growth factors (bone morpho-
genetic protein — BMP), transforming growth factor b (TGFb), 
and fibroblast growth factor (FGF) stimulate osteoblast precursor 
cells for maturation. Osteoprotegerin (OPG) produced by these 
cells is the main inhibitor of osteoblast maturation and belongs to 
the RANK/RANKL/OPG system which plays a fundamental role in 
bone remodelling processes [5, 6]. 
Classifications and consequences of bone 
metastases
The most common localization of metastatic lesions is often 
connected with the site of primary focus and anatomic condi-
tions — direct vascular connections between the main vein 
systems, portal vein, and pulmonary vein with spinal veins cause 
frequent metastases to the spine in the course of prostatic and 
breast cancer. Tumour dissemination to bones typically has a mul-
ti-focus nature. 
Table 2 presents the most common localization of metastatic 
lesions out of 100% of patients with diagnosed metastases ac-
cording to different data [7–10]. 
A few classifications of stage progress in bone neoplastic 
dissemination can be found. In orthopaedics, the most com-
monly used classification is the one by Yamashita presented in 
Table 3 [11]. 
As regards nuclear medicine, the Solovay scale or Bone Scan 
Index (BSI) are used much more frequently [12–15]. 
The general condition of a patient with bone metastases is typi-
cally connected not with the presence of metastases but rather with 
its consequences — the so-called skeletal-related events (SRE). 
The latter can be divided into: directly induced by the presence of 
neoplastic cells in bone (CIBD — cancer-induced bone disease) 
and related to loss of bone mass as a result of treatment (CTIBL 
— cancer treatment-induced bone loss), e.g. in antiandrogenic 
therapy of prostatic cancer. Another significant parameter is the 
period of time until the moment of occurrence of the first seri-
ous bone event — the time to a skeletal-related event (TTSRE) [1]. 
The most common SREs are: pathologic fracture of vertebrae or 
other bones (up to 25%), spinal cord compression (up to 8%), hy-
percalcaemia (up to 25%), and necessary surgical treatment (up to 
4%) or radiotherapy (up to 33%) due to clinical symptoms [1, 16, 17]. 
However, the presence of bone metastases typically causes pain 
that occurs in over 70% of patients. Bone tissue has rich neuration, 
mainly from the periosteum, but as it has been recently found that 
the endings of nerve fibres also reach the medullary cavities in long 
bones (medullary membrane) and parts of cancellous bones [18]. 
Pain pathogenesis in metastasis has not been fully understood 
and in most cases has multiple causes. However, it seems that 
the following factors are the most significant [18, 19]:
A. Mechanical factors that stimulate bone nociceptors:
—  compression connected with bone remodelling and peri-
osteum damage;
—  increased pressure inside bone;
—  bone deformation due to osteolysis;
—  direct compression of metastatic tissue on nerves or sur-
rounding soft tissue;
—  pathologic fractures that change bone compression dis-
tribution (e.g. vertebra compression fractures).
B. Chemical mediators influencing nociceptors:
—  mediators activated or produced by neoplasm (e.g. TGF, 
TNF, IL);
—  activation of arachidonic acid cascade (prostaglandin E).
C.  Other factors:
Table 2. The most common localization of bone metastatic lesions 
The most common 
metastasis localization
Lesion percentage (%)
Lumbar spine 65–72
Sacral spine 65–68
Pelvis 60–66
Ribs 50–62
Cranial bones 35–44
Femora 30–44
Cervical and thoracic spine 25–40
Table 3. Yamashita classification
Progression 
stadium
Central skeleton 
(lumbar and thoracic spine, ribs)
Medial skeleton 
(pelvis, cranium, cervical spine)
Peripheral skeleton 
(sternum, scapulae, femoral and humeral bones)
Stadium I Yes No No
Stadium II Yes Yes No
Stadium III Yes Yes Yes
98
Nuclear Medicine Review 2011, Vol. 14, No. 2
www.nmr.viamedica.pl
Review
—  disturbances in blood supply and outflow.
Symptoms related to bone metastases cause considerable 
deterioration of the life quality and health condition of the pa-
tients and also shorten their life in a statistically significant way. 
Bone metastases diagnostics is based on taking history, 
clinical examination, imaging studies, and biochemical tests. 
A thorough history completed by a clinical examination allows de-
termination of the location of painful metastatic lesions in 90% 
of cases. It also allows for the establishment of the nociceptive 
nature of the pain which in almost 70% of cases accompa-
nies neuropathic pain. 
Bone metastatic lesion imaging 
and determination of bone remodelling type
In imaging diagnostics of bone metastases, plain X-ray of 
a particular skeletal element is used as well as computed to-
mography (CT), magnetic resonance (MRI), positron emission 
tomography (PET), and tests with the use of nuclear medicine 
techniques (SPECT planar scintigraphy). Basic radiologic clas-
sification of bone metastases differentiates osteolytic and oste-
oblastic types. In practice, bone metastases are never of uniform 
nature. It is more accurate to describe them as metastases with 
a dominant osteolytic process and a dominant process of osteo-
sclerosis, while in the case of no dominance — mixed metas-
tases (osteolytic-osteoblastic) (Table 4) [1, 20]. 
Determination of bone remodelling type is extremely signifi-
cant in making decisions connected with patient qualification for 
metastases treatment. Bone metastases from various organs are 
different in terms of their effect on osteoclast and osteoblast func-
tion. Increased pathologic stimulation of an osteoclast leads to 
intensification of osteolysis with concurrent tendency for hyper-
calcaemia. Increased osteoblast stimulation causes overproduc-
tion of bone matrix with secondary hypercalcification and is very 
rarely accompanied by a tendency for hypercalcaemia. In these 
patients calcium concentration is much more frequently close to 
the lower limit and is accompanied by increased levels of alkaline 
phosphatase. However, both described situations occur at the 
same time in a large group of patients (Figure 2) [7–10, 21].
Plain radiograms have considerably low sensitivity in detect-
ing early changes in bone matrix density caused by the presence 
of neoplastic cells. In the past, limit values of detecting meta-
static focus in X-rays were lesions with a diameter over 10 mm 
and change in bone matrix density of 40–50% compared with 
surrounding healthy tissue. Currently, as X-ray apparatus have 
increasingly better quality (digital techniques) which allows a pre-
cise computer analysis of the obtained image, detection sensi-
tivity is evidently rising. It is extremely important from a clinical 
standpoint as in the case of prostatic cancer approximately 
40% of spine metastases is detected during pain syndrome 
diagnostics treatment based on initial diagnosis of degenerative 
spinal disease [22]. 
Currently, computed tomography seems to be a sufficient 
study for clear diagnosis of bone metastases. It allows, especially 
with the use of multi-row detector CT,  precise evaluation of both 
the extent and nature of the lesion. In exceptional cases, most 
commonly of single lesions, the necessity of additional differential 
diagnostics between neoplastic and inflammatory osteolysis or 
neoplastic and degenerative osteosclerotic process might arise. 
Magnetic resonance, similarly to CT, shows high sensitivity 
(over 70%) and specificity (almost 100%) in detecting metastatic 
lesions and allows for differentiation of osteoblastic and osteolytic 
foci. Low focus intensity in T1 weighted time, and increased in T2 
weighted, suggests osteolysis, while reduction of signal in T1 and 
T2 weighted indicates osteoblastic nature of metastasis. Whole 
body MRI (MR-WBS) in T1 and T2 weighted sequences, including 
STIR, with application of paramagnetic contract appears to be 
particularly useful — sensitivity over 90%. Apart from revealing 
bone metastases, it also allows for evaluation of neoplasm inva-
siveness in bone marrow [23].
Table 4. Most commonly observed variants of bone metastases 
depending on primary focus site
Primary focus Metastases properties
Prostate
Osteoblastic (75%) mixed 
and osteolytic (25%)
Breast
Osteolytic (65%) mixed 
and osteoblastic (35%)
Lung, kidney, pancreas, 
oesophagus, melanoma
Osteolytic
Stomach Osteoblastic/mixed
Large intestine Osteolytic/mixed/osteoblastic
Figure 2. Mechanisms inducing bone remodelling in bone metastatic focus. IL — interleukin; TNF — tumor necrosis factor; TGF — tumor 
growth factor; EGF — epidermal growth factor; PTH-rP — parathyroid hormone-related protein; PGE — prostaglandin E; MCSF — macrophage 
colony-stimulating factor.
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PET study is not a target method for bone metastases diagnos-
tics (due to economically unfavourable ratio of test effectiveness to 
test cost). Also, in order to obtain the best diagnostic outcomes, 
18-NaF ought to be applied (high affinity to hydroxyapatite) and 
not 18-fluorodezoxyglucose (18-FDG), which is a typical metabolic 
tracer and provides a number of additional diagnostic data in most 
neoplastic patients [24]. 
Commonly used PET-CT with 18-FDG in the case of high dif-
ferentiation of neoplastic cells, low metabolism of primary lesion 
and metastatic lesions might give false negative results, especially 
in skeletal system foci.
Currently, the fundamental study in bone metastases diag-
nostics is still scintigraphy. In the skeletal system this study con-
firms neoplastic dissemination to bone but also provides additional 
data on the extent and localization of the lesions. Scintigraphy 
sensitivity in detecting metastatic lesions might even be a few 
times higher compared to plain X-ray. It detects foci of abnormal 
bone metabolism (mainly neoplastic metastases) even of 1–2 mm 
in size and bone matrix density change of approximately 10%. 
Unfortunately, scintigraphy clearly loses its value compared to 
MR-WBS [25–28]. However, scintigraphy sensitivity might be 
increased from 70% to over 80% by using SPECT technique. A fur-
ther considerable increase in sensitivity is possible by conducting 
studies with SPECT-CT. Introduction of new informatics techno-
logy, which has been suggested by recent reports, might increase 
scintigraphy sensitivity to as much as 89% [29, 30]. According 
to many opinions, no dominance of the MR-WBS method over 
classic scintigraphy can be found in clinical practice. Both stu-
dies performed concurrently complete each other perfectly. Low 
specificity remains a crucial issue in scintigraphy. Routinely applied 
carriers in isotopic diagnostics are 99mTc labelled phosphonate 
compounds (the most commonly used is methylene diphospho-
nate — MDP) which accumulate in all the sites of increased bone 
metabolism within a newly-formed bone due to chemiabsorption 
and phosphonate complex exchange. In certain cases, only a thor-
ough history and the said additional imaging tests are sufficient 
to differentiate potentially metastatic lesions with post-trauma, in-
flammatory, and necrotic lesions. Based on scintigraphic study (in 
contrast to the imaging studies described above) it is not possible 
to clearly determine the type of metastasis and fracture presence. 
A number of cases in bone metastases diagnostics require 
“overlaying” diagnostic images with the use of at least two tech-
niques. In clinical practice it is recommended to combine isotopic 
studies and radiology (X-ray, CT, MRI), which is partly possible due 
to modern gamma cameras. This is critical in the case of qualifica-
tion for isotopic treatment — foci lesions, like bone metastases that 
are not always visible in MRI or CT, must intensely accumulate 
phosphonate derivatives used in diagnostic and therapeutic 
isotope techniques (Figure 3). This works the other way round 
as well — intense accumulation of MDP-Tc99m in scintigraphy that 
qualifies patients for treatment does not exclude the presence of 
unstable pathologic fractures or a large lytic focus which carries the 
risk of fracture and requires urgent orthopaedic and neurosurgical 
attendance in the first place (Figures 4–6). 
Biochemical diagnostics of bone metastases has been the 
subject of numerous discussions on the possibilities of using bone 
turnover markers in oncology. The American Society of Clinical 
Oncology suggests labelling calcium concentration and potential 
bone alkaline phosphatase (BALP) and also indicates that routine 
labelling of bone turnover markers in monitoring the course of 
treatment should not be recommended, despite its usefulness in 
certain cases [31–33]. 
To conclude all the above data, the following course of action 
might be suggested in cases of suspected bone metastasis in 
order to chose proper treatment, including isotopic therapy:
1.  Confirmation of the presence and stage of metastases (bone 
scintigraphy, X-ray, CT, MRI, PET).
2.  Evaluation of bone metastasis nature — osteolytic, osteoscle-
rotic, or mixed (typically in the case of larger foci X-ray is suf-
ficient) and exclusion of the presence of especially unstable 
pathologic fractures as well as evaluation of potential risk of 
spinal core compression.
3.  Hypercalcaemia risk evaluation (calcium concentration in 
blood serum, localization of primary focus — the highest risk 
of hypercalcaemia occurs in cancer of the lungs, breast, and 
kidney as well as myeloma).
Figure 4. Osteolytic lesions in the femur with subsequent pathologic 
fracture in a 67-year-old woman with kidney cancer.
Figure  3. Disseminated metastatic lesions in the bone with pathologic 
vertebra fracture clearly visible only in MRI (70-year-old man with 
palatine tonsil cancer and prostate cancer).
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4.  Aspirative biopsy in the case of difficulties with determining 
primary focus.
Treatment possibilities in bone metastases
Forms of therapy used in bone metastases treatment are 
presented in Figure 7. Possibilities of combining isotopic therapy 
with other treatment methods will be discussed further in the work. 
Radioisotope application in the treatment 
of bone metastases
The destruction of at least some neoplastic cells in bone 
metastatic foci due to ionizing radiation causes a considerable 
decrease in local release of both inflammatory and pain reac-
tion mediators. Concurrently, metastatic mass is reduced, which 
leads to a decrease in mechanical stimulation of pain receptors. 
Treatment with radioactive isotopes is more and more frequently 
used in early stages of bone metastases therapy. It is supposed 
to prevent development of pain symptoms and other complica-
tions. In Poland, two isotopes are currently applied in bone me-
tastases isotopic therapy: strontium-89 (Sr89) and samarium-153 
(Sm153) instead of previously used phosphorus 32 (P32) [34–37]. 
Emitters of a radiation (mainly radium — 223) are still examined 
in clinical trials [38, 39]. 
Strontium-89
Strontium-89 is a pure b radiation emitter and calcium ana-
log. It is uptaken and incorporated into collagen in all the sites of 
increased bone remodelling, with pathologically stimulated os-
teoblast, which is typical mainly of osteosclerotic foci of bone 
metastases. The biological half-life of Sr89 isotope amounts to 50.5 
days. Therefore, doses might be small as the therapeutic effect 
will last long after incorporation into osteoblastic focus. The drug 
is administered intravenously (like strontium chloride), while the 
main means of isotope elimination are the kidneys (up to 90%).
Samarium-153
Samarium-153 is applied intravenously in the form of chelate 
compound with tetraphosphonate (Lexidronian), which deter-
mines the high sensitivity and specificity of drug accumulation in 
sites of bone remodelling (high affinity to hydroxyapatite) caused 
by the presence of neoplastic cells. Sm153 emits b therapeutic radia-
tion and low-energy g radiation, which allows post-therapeutic ima-
ges to be obtained with the use of gamma cameras. Sm153 half-life 
period amounts to 1.9 days, which determines the necessity of 
applying high activities yet makes this treatment similar to classic 
teleradiotherapy (large dose in a short time) — it is sufficient for 
a therapeutic effect that the radioisotope bonds with hydroxyapatite 
for a short time. The main path of eliminating the isotope that is not 
bonded by bone tissue are the kidneys, as in the case of Sr89. 
Rules of qualification for metastases 
treatment with the use of radioisotopes
Qualification for isotope therapy includes the following fac-
tors is listed below.
Nature of metastasis
Principally, osteoblastic or mixed metastases are an indication 
for radioisotope therapy; osteolytic metastases require bisphos-
phonate treatment in the first place. 
The mechanisms of radioisotope bonding in metastatic foci 
described above cause similar Sr89 and Sm153 effectiveness in 
osteoblastic bone metastases (approximately 75–80% positive 
response to monotherapy). In the case of Sm153, a lytic osteoblastic 
lesion with a large amount of hydroxyapatite bonds the thera-
peutic complex well. In the case of Sr89 therapy, high osteoblast 
Figure 5. Osteosclerotic lesions in the pelvis and tibia in 
an 82-year-old man with prostate cancer.
Figure  6. Pathologic fracture of the right femur revealed in X-ray 
during qualification for radioisotope therapy (65-year-old patient with 
prostate cancer).
Figure  7. Forms of therapy applied in bone metastatic lesions.
Pain farmacotherapy
Teleradiation Hormonetherapy
Izotope therapy Chemotherapy
Bisphosphonates Surgical treatment
How to treat?
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activity allows for incorporation of a large amount of isotope into 
pathologically changed osteosclerotic bone matrix. The effective-
ness of mixed metastases therapy decreases in inverse proportion 
to the increase in osteolytic component, especially in large foci 
(analgesic effect in monotherapy decreases to 20–40%). Based 
on numerous reports it can be assumed that it is the type and size 
of metastasis, and secondly neoplasm type, that dictate therapy 
effectiveness. Reports on good treatment effectiveness refer not 
only to prostate and breast cancer patients but also to individu-
als with cancer of the kidney, urinary bladder, and lungs as well 
as osteosarcoma [38–42].
Intensity, localization, size, and number of tracer 
accumulation foci in bone scintigraphy 
The multi-focus nature of metastatic lesions is one of the 
basic indications for radioisotope treatment. Quantitative meas-
urement of skeletal system involvement might be performed by 
the above-mentioned Solovay scale or BSI calculation. The more 
intense the radiotracer accumulation and the smaller the focus, 
the better the treatment effectiveness expected. The presence or 
high risk of pathologic fractures, particularly in the spine, indices of 
mechanical compression of nerve roots or vertebral cord constitute 
a contraindication for radioisotope therapy. The patient might be 
qualified for isotope treatment again following interventional ortho-
paedic procedure, interventional radiotherapy, or intensive intrave-
nous bisphosphonate therapy. Patients with bone metastases and 
superscan scintigram might be problematic. The author’s own 
observations suggest a good expected effect of the treatment, 
yet the risk of serious haematological complications amounts to 
approximately 50%, which indicates the need for care in calculating 
the dose — reduction by at least 25% is recommended [40, 41].
Patient general condition and life expectancy 
It is generally acknowledged that life expectancy in a patient 
qualified for radioisotope therapy should not be shorter than 
2–3 months. Poor general condition and considerable cachexia 
might also be direct causes of patient disqualification from the 
treatment. The first pain symptoms occur approximately after 
7–14 days following dose administration and can be observed 
for as long as a year [43–46].
Bone marrow damage indices 
Characteristics of bone marrow damage (E < 3.0 T/l, 
Hb < 10 g%, L < 3.000 G/l — recommended smear for deter-
mining absolute granulocyte number, which should not be lower 
than 1.500 G/l; PLT < 100.000–60.000 G/l) that might be directly 
connected with neoplastic disease or previous treatment (e.g. 
aggressive chemotherapy or radiotherapy) might disqualify the 
patient from the treatment. Administration of radioisotope dose 
to patients with bone marrow damage carries a risk of full-blown 
thrombocytopaenia, leucopoenia or anaemia [10, 34, 36, 37].
Renal failure and urine retention or urine 
incontinence
A lack of possibilities to eliminate a radioisotope from pa-
tient’s body might lead to drug accumulation and an increase in 
potential side effects. Also, infection of potential catheters, urine 
bags, nephrofixes, etc. applied in patients with retention or incon-
tinence constitute a significant problem. Although, this issue is not 
an absolute contraindication for radioisotope therapy in ambulatory 
conditions of drug administration, it is connected with high risk of 
contamination persons who take direct care of the patient [47, 48]. 
Parameters of calcium-phosphorus metabolism
Every bone metastases patient requires regular check of 
calcium concentration in blood serum. Patients that take calcium 
preparations (for different indications) should discontinue about 
10 days prior to scheduled strontium isotope treatment (potential 
uptake competitiveness). Failure in meeting this requirement 
might considerably reduce Sr89 uptake by bone metastases foci 
and thus significantly decrease treatment effectiveness. In the 
case of patients qualified for Sm153 therapy it is recommended to 
discontinue bisphosphonate administration for a period of 2–4 
weeks (potential impediment of Sm153 tetraphosphonate uptake). 
However, in 2008 and 2009 Lam published two works connected 
with prostate cancer patients. The author showed that zolen-
dronate, similarly to pamidronate, does not decrease uptake of 
samarium 153Sm isotope. The treatment had high effectiveness and 
significantly low toxicity [49, 50]. 
Other forms of parallel oncologic and symptomatic 
therapy 
Most types of chemotherapy, due to potential myelotoxic effect, 
might block radioisotopic treatment. According to many reports, 
it is possible to conduct parallel local radiotherapy from external 
sources before and during isotopic treatment (potential strength-
ening effect). Radioisotopic treatment might be a continuation of 
radiotherapy in the case of exceeding the upper dose absorbed from 
external sources or risk of local complications of local radiotherapy. 
The pros and cons of combining radioisotopic therapy with other 
forms of oncologic treatment are presented in Table 5 [51–56].
No clear interactions between concurrent application of bi-
sphosphonate and Sr89 have been observed (different uptake point 
in the bone). Moreover, bisphosphonate administration prior to Sr89 
injections might have a beneficial impeding effect on osteoclast 
activity and allow for osteoblast dominance, which increases the 
possibility of greater radiopharmaceutical accumulation in the 
metastatic focus. Bisphosphonate administration directly after radio-
isotope injection practically eliminates the risk of hypercalcaemia 
development (15%) as a consequence of radiopharmaceutical 
administration. No reports on Sm153 isotope interactions with calcium 
preparations can be found. As mentioned above, in patients treated 
with Sm153 it is recommended to withdraw bisphosphonate prepa-
Table 5. Pros and cons of combining isotope therapy with other 
treatment forms
Isotope therapy
Effectiveness 
increase
Risk of undesirable 
effects
With radiotherapy High Moderately increased*
With bisphosphonates High**/moderate Low
With chemotherapy High**/moderate High***
With hormone therapy High/moderate Low
*depends on total absorbed dose; **especially in breast cancer; 
***depends on chemotherapy type
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rations for 2–4 weeks prior to scheduled isotope treatment. Their 
administration on the third day following the treatment is believed 
to be beneficial. Similarly to Sr89 therapy, the risk of post-therapeutic 
hypercalcaemia is almost absolutely eliminated. This scheme of 
combining Sr153 therapy with bisphosphonates is particularly recom-
mended in patients with metastases that show osteolytic component 
and hypocalcaemic tendency [57–60].
Radioisotope choice
As mentioned above, both Sm153 and Sr89 have similar effec-
tiveness in osteoblastic bone metastases treatment. In the case of 
mixed metastases the therapy effectiveness decreases, especially 
with Sr89. Thus, such patients should be prescribed Sm153 isotope 
therapy. The reason is the disproportion of osteoblast and osteoclast 
activity in mixed metastases, especially with the dominance of oste-
olysis. The possibility of fast incorporation and longer “maintenance” 
of Sr89 isotope is considerably reduced, which leads to a decrease 
in absorbed therapeutic dose and final therapeutic effect. Higher ef-
fectiveness of Sm153 is probably a result of less specific mechanism 
of bonding therapeutic complex to hydroxyapatite — a large dose of 
a radiopharmaceutical will always give at least a partially therapeutic 
effect even when it is bonded to a lesser extent and for a short time 
[21, 43, 44, 57, 58, 61]. According to observations, Sr89 isotope 
has slightly higher and often delayed myelotoxicity, especially in 
younger individuals and multiple therapies. Some observations in-
dicate that every subsequent therapeutic dose administered might 
give a long lasting effect of decreasing blood platelet and leukocyte 
concentrations by a subsequent 10% compared to initial values. The 
impact on the red blood cell system is approximately 50% smaller. 
As regards the percentage of early clinically significant yet typically 
mild and spontaneously subsiding haematological complications, 
it is quite similar for both isotopes and amounts to approximately 
25%, which is confirmed by literature reports. The risk of their oc-
currence not only rises proportionally with each subsequent dose 
administered but it is also a result of previously (or simultaneously) 
applied treatment, e.g. radiotherapy, chemotherapy, or hormone 
therapy, as well as symptomatic analgesic treatment. The analgesic 
effect of Sm153 occurs slightly sooner than in the case of Sr89. How-
ever, some authors claim that it is also shorter and requires more 
frequent treatment renewal [7, 10, 34, 36, 61].
Radioisotope dosage
Both Sr89 chloride and Sm153 tetraphosphonate are admin-
istered intravenously in a one-time injection. In the case of Sr89 
a standard dose of 150 MBq — 4 mCi is typically administered 
or is calculated as follows: from 1.1 to 3.0 MBq/kg of body mass. 
As regards Sm153, the starting therapeutic dose is calculated 
as follows: 37 MBq/kg of body mass. The most common indica-
tions for reduction of the calculated dose by 25–50% are limit 
haematological parameters and signs of moderate renal failure. 
Radioisotope therapy might be repeated many times, providing 
its effect is satisfactory and no side effects are observed. Typically, 
a patient is not qualified for next dose if visible side effects were 
seen or no improvement was observed. However, in the latter 
case a change of the applied isotope could be considered, espe-
cially from Sr89 to Sm153. According to current Polish regulations, 
bone metastases therapy with the use of Sr89 and Sm153 might be 
conducted in ambulatory conditions in nuclear medicine depart-
ments that meet certain conditions. Due to the nature of the applied 
isotopes, the patient does not pose a direct threat to their surround-
ings, providing that certain precautions are undertaken [47, 48].
Treatment effectiveness
Treatment effectiveness depends on a few factors [51–56]:
1.  Quantity, localization, and size of metastatic lesions in the bone. 
The more foci, the greater the lesion diameter and presence 
of potential cracks or fractures (especially vertebral), the 
greater the component of neuropathic pain, the poorer the 
treatment effect.
2.  Scheme of treatment (monotherapy or therapy combined 
with radiotherapy and/or bisphosphonates) and the size of 
administered dose (Table 6). 
Post-therapeutic patient control 
and potential undesirable effects
The first control after the treatment should take place after ap-
proximately 2 weeks, the second between the 4th and 6th weeks, 
and the third between the 8th and 12th weeks. The follow up should 
include evaluation of analgesic effect, neurologic condition control 
examination (especially in metastases to the spine), and evalua-
tion of haematological parameters (obligatorily blood count with 
platelets and smear), calcaemia level, and individual evaluation 
of renal and hepatic parameters as well as neoplastic markers. 
The following potential undesirable effects should be taken into 
consideration: 
—  increased pain symptoms (in 10–20% of patients “flare syn-
drome” might develop), especially in the cases of presence of 
neuropathic pain (nerve compression etc.) — prophylactics or 
reduction of the said complaints is possible by short use of gly-
cocorticosteroids (e.g. dexamethasone 4 mg/a day in a dose 
decreasing by 1 mg every 5–7 days). Prior to glycocorticos-
teroid administration a history should be taken as regards the 
presence of direct and indirect contraindications for this type 
of therapy, and the patient should be informed about possible 
undesirable effects of the drug;
—  temporary impediment of bone marrow function. A decrease 
in the number of platelets and leukocytes is observed most 
commonly between the 2nd and 8th weeks after administration 
of radioisotope dose and typically does not exceed 30–50% 
of starting parameters. Very rarely is it necessary to hospital-
ize patients due to myelotoxic complications in radioisotope 
therapy and with proper qualification. Such a necessity is pro-
Table 6. Effectiveness of isotope monotherapy and monotherapy 
combined with local radiotherapy
Treatment effect
Isotope 
monotherapy
Isotope therapy 
with local radiotherapy
Total pain relief 30–40 % 50–65 %
Partial pain relief 40–50 % 20–30 %
Unsatisfactory effect 20% 15–20 %
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portional to the large number and massiveness of metastatic 
lesions diagnosed in the skeletal system. This risk increases in 
the case of previous treatment of high myelotoxicity probability 
as well as numerous clinical signs of neoplastic infiltrate within 
bone marrow;
— hypercalcaemia. It develops rarely. An increase in calcium 
concentration is connected with osteolysis in metastatic foci 
and is typically short and easy to control with bisphospho-
nates; 
— pathologic fractures. Intensive post-therapeutic osteolysis of 
large metastatic foci that were earlier connected with high 
risk of fracture might lead (especially in patients who showed 
pain relief and sudden increase of life activity) to pathologic 
fractures. Such probability is more common in mixed metas-
tases patients or those with clear domination of osteolysis lo-
calized in the spine, pelvis, or femora. In such cases standard 
combination of isotopic therapy with bisphosphonate treat-
ment might be particularly beneficial [9, 57–59].
Economic aspect of radioisotope therapy
The cost of pain treatment with the use of radioiso-
topes is less than half the cost of conservative treatment. As re-
gards isotope therapy patients, no clear statistical data regarding 
lengthening of life can be found. However, these patients report 
improved life quality, and a lower number of both pathologic 
fractures and clinical circumstances requiring hospitalization 
is observed [45, 61–63]. 
Conclusions 
1.  Radioisotopes are effective drugs in the treatment of oste-
oblastic and mixed bone metastases, in monotherapy and in 
combination with radiotherapy. 
2.  Radioisotope treatment in the case of diagnosing bone metas-
tases might be applied even prior to development of clinical 
symptoms, which reduces the number of new pain sites and 
the risk of pathologic fractures. 
3.  Radioisotope treatment considerably raises quality of life and 
reduces both pain and necessity of administering analgesics. 
4.  Radioisotope therapy causes statistically significant reduction 
of treatment costs in bone metastases patients.
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